STrategies for AntithRombotic Treatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant

Inclusion Criteria: * Patients who had undergone successful TEER (Defined as techinal success according to MVARC ); * Ability to understand the requirements of the trial and willingness to comply with the trial protocol procedures; * Provide written informed consent form； * Women of childbearing potential must use an acceptable method of contraception from signing the informed consent form until the date of the last dose of antithrombotic drug; * The heart team agrees on the antithrombotic strategies. Exclusion Criteria: * Severe renal impairment (creatinine clearance rate\<15ml/min or on dialysis); * Postoperative persistent bleeding (overt bleeding either associated with a drop in the hemoglobin of 3.0 g/dl or requiring transfusion of 3 U of whole blood or packed red blood cells) or occurrence of vascular complications; * Platelet count≤30×10\^9/L; * Need for reoperation; * History of intracranial or intracerebral hemorrhage; * History of gastrointestinal ulcers or hemorrhage; * Any hepatic disease associated with coagulopathy (Child-Pugh B or C); * Allergy, intolerance or contraindication to oral anticoagulation or antiplatelet drug; * Need for long-term oral anticoagulation; * Current double antiplatelet therapy； * Patients who have participated in another drug or device investigational study within the past 30 days; * Life expectancy \<12 months; * Pregnant or breastfeeding women.